Literature DB >> 28838799

The potential contribution of 16S ribosomal RNA polymerase chain reaction to antimicrobial stewardship in culture-negative infection.

S O'Donnell1, L Gaughan2, M Skally2, Z Baker2, K O'Connell3, E Smyth3, F Fitzpatrick3, H Humphreys3.   

Abstract

Empiric broad-spectrum antimicrobial therapy frequently results in culture-negative specimens making rationalization of therapy difficult. We retrospectively reviewed 16S rRNA polymerase chain reaction (PCR) results from 78 specimens in 60 patients. 16S rRNA was detected in 28 (47%) patients with de-escalation of therapy in five (21%). Microbial DNA was not detected in 32 (53%) patients with antimicrobials discontinued in two (8%). Neurosurgical patients had a higher proportion of positive results (53% vs 34%) and treatment rationalizations (17% vs 12%). In specific patient groups, 16s rRNA PCR is a useful antimicrobial stewardship tool for targeting antimicrobial therapy.
Copyright © 2017 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  16S rRNA PCR; Antimicrobial stewardship; Cost analysis; De-escalation; Empiric antimicrobials; Neurosurgery

Mesh:

Substances:

Year:  2017        PMID: 28838799     DOI: 10.1016/j.jhin.2017.08.016

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  2 in total

1.  Diagnostic Value of 16S Ribosomal RNA Gene Polymerase Chain Reaction/Sanger Sequencing in Clinical Practice.

Authors:  Madiha Fida; Sarwat Khalil; Omar Abu Saleh; Douglas W Challener; Muhammad Rizwan Sohail; Joshua N Yang; Bobbi S Pritt; Audrey N Schuetz; Robin Patel
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 20.999

2.  Infected simple renal cyst due to Streptococcus pneumoniae rapidly diagnosed by the melting temperature mapping method: a case report.

Authors:  Yoji Uejima; Hideki Niimi; Reiko Kato; Mihoko Furuichi; Satoshi Sato; Isao Kitajima; Yutaka Kawano; Tsutomu Oh-Ishi; Hiroshi Kawashima; Eisuke Suganuma
Journal:  BMC Pediatr       Date:  2021-06-05       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.